E-LIB Suche - Ergebnisse für: de Marinis, F.

1

27P CNS-progression patterns in patients with EGFR-mutant N..:

Attili, I. ; Corvaja, C. ; Spitaleri, G....
ESMO Open. 9 (2024) - p. 102606 , 2024

Link: https://doi.org/10.1016/..

2

P1.25-09 TARGET: A Phase II Study of 5-year Adjuvant Osimer..:

Soo, R. ; De Marinis, F. ; Han, J.-Y....
Journal of Thoracic Oncology. 18 (2023) 11 - p. S272 , 2023

Link: https://doi.org/10.1016/..

3

44P Dostarlimab (Dos) or pembrolizumab (Pem) + chemotherapy..:

Granados, A.L.O. Ortega ; Lim, S.M. ; Schenker, M....
Journal of Thoracic Oncology. 18 (2023) 4 - p. S67-S68 , 2023

Link: https://doi.org/10.1016/..

4

92P Predictors, surrogate and patient-reported outcomes in ..:

Bertolaccini, L. ; Mohamed, S. ; Galetta, D....
Journal of Thoracic Oncology. 18 (2023) 4 - p. S94-S95 , 2023

Link: https://doi.org/10.1016/..

5

Safety of mRNA-COVID-19 Vaccines in Patients With Thoracic ..:

Spitaleri, G. ; Trillo Aliaga, P. ; Catania, C....
Clinical Lung Cancer. 24 (2023) 1 - p. e19-e26 , 2023

Link: https://doi.org/10.1016/..

6

Immunotherapy in the first-line treatment of elderly patien..:

Gridelli, C. ; Peters, S. ; Velcheti, V...
ESMO Open. 8 (2023) 2 - p. 101192 , 2023

Link: https://doi.org/10.1016/..

7

LBA2 First-line (1L) durvalumab (D) + platinum-etoposide (E..:

Reinmuth, N. ; Özgüroğlu, M. ; Leighl, N.B....
Immuno-Oncology and Technology. 20 (2023) - p. 100692 , 2023

Link: https://doi.org/10.1016/..

8

OA21.05 Tepotinib + Osimertinib in EGFR-mutant NSCLC with M..:

Kim, T.M. ; Guarneri, V. ; Jye, V.P....
Journal of Thoracic Oncology. 18 (2023) 11 - p. S94 , 2023

Link: https://doi.org/10.1016/..

9

3P Exploratory efficacy analysis by smoking status in PD-L1..:

Paz-Ares, L. ; García-Campelo, M.R. ; Isla Casado, M.D....
Immuno-Oncology and Technology. 20 (2023) - p. 100474 , 2023

Link: https://doi.org/10.1016/..

10

OA15.04 Comparison of Digital Vs Manual PD-L1 Tumour Cell S..:

Herbst, R.S. ; Ruderman, D. ; Conway, J....
Journal of Thoracic Oncology. 18 (2023) 11 - p. S79-S80 , 2023

Link: https://doi.org/10.1016/..

11

OA01.09 Adjuvant Osimertinib in Resected EGFR-Mutated Stage..:

Herbst, R.S. ; Wu, Y.-L. ; Grohe, C....
Journal of Thoracic Oncology. 18 (2023) 3 - p. e4 , 2023

Link: https://doi.org/10.1016/..

12

EP07.04-06 ALK Rearrangement Is Associated with Early Lymph..:

Gallina, F.T. ; Tajè, R. ; Cecere, F.L....
Journal of Thoracic Oncology. 18 (2023) 11 - p. S545-S546 , 2023

Link: https://doi.org/10.1016/..

13

170P Preliminary results from LUMINANCE: A phase IIIb, sing..:

Reinmuth, N. ; de Marinis, F. ; Leighl, N....
Journal of Thoracic Oncology. 18 (2023) 4 - p. S134 , 2023

Link: https://doi.org/10.1016/..

14

EP08.02-048 Crizotinib in ROS1+NSCLC: Long-term OS Analysis..:

Cappuzzo, F. ; Chiari, R. ; Tiseo, M....
Journal of Thoracic Oncology. 17 (2022) 9 - p. S421 , 2022

Link: https://doi.org/10.1016/..

15

First-line immunotherapy in advanced non-small-cell lung ca..:

Gridelli, C. ; Peters, S. ; Mok, T....
ESMO Open. 7 (2022) 1 - p. 100355 , 2022

Link: https://doi.org/10.1016/..